Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients
Table 2
Frequency of clinical manifestations and association with urinary microRNAs excretion profile indicative of renal fibrosis in Fabry disease patients.
Frequency (%)
Association with microRNAs urinary excretion profile indicative of renal fibrosis. Pearson correlation ( value)
Reduced αGalA activity
9/24 (37.50)
0.548 (0.006)
Male gender
7/24 (29.16)
0.454 (0.026)
Neuropathic pain
13/24 (54.16)
0.414 (0.044)
Hipohidrosis
10/24 (41.66)
0.598 (0.002)
GI symptoms
11/24 (45.83)
0.296 (0.161)
Angiokeratomas
12/24 (50.00)
0.530 (0.008)
Hearing loss
6/24 (25.00)
0.408 (0.048)
Pathological Albuminuria
5/24 (20.83)
-0.29 (0.169)
Reduced eGFR
0/24 (0.00)
- (+)
Cardiac involvement
6/24 (25.00)
0.408 (0.048)
CNS involvement
5/24 (20.83)
0.363 (0.081)
ERT treatment
9/24 (37.50)
0.365 (0.079)
RAAS inhibitors Treatment
6/24 (25.00)
0.408 (0.048)
The correlation is significant at the 0.05 level (bilateral) The correlation is significant at the 0.01 level (bilateral) (+) Can not be calculated because the “reduced eGFR” variable is constant References: αGalA: α-galactosidase-A; GI: gastrointestinal; eGFR: estimated glomerular filtration rate; CNS: nentral nervous system; ERT: enzyme replacement theraphy; RAAS: renin-angiotensin-aldosterone system.
